PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
New brain-penetrant agonist shows promise in protecting dopamine neurons for Parkinson’s disease treatment
Researchers reported on Nurr1 as a promising therapeutic target for managing Parkinson’s disease (PD).